ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - desogestrel 150 µg; ethinylestradiol 30 µg - tablet - 150 µg - 30 µg - desogestrel 150 µg; ethinylestradiol 30 µg - desogestrel and ethinylestradiol

ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol 0,03 mg; levonorgestrel 0,15 mg - filmomhulde tablet - 30 µg - 150 µg - ethinylestradiol 30 µg; levonorgestrel 150 µg - levonorgestrel and ethinylestradiol

ベルギー - フランス語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - désogestrel 150 µg; ethinylestradiol 30 µg - comprimé - 150 µg - 30 µg - désogestrel 150 µg; ethinylestradiol 30 µg - desogestrel and ethinylestradiol

ベルギー - フランス語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol 0,03 mg; lévonorgestrel 0,15 mg - comprimé pelliculé - 30 µg - 150 µg - ethinylestradiol 30 µg; lévonorgestrel 150 µg - levonorgestrel and ethinylestradiol

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus

ドイツ - ドイツ語 - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - buprenorphin - transdermales pflaster - 30 mikrogramm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 30 milligramm

ドイツ - ドイツ語 - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 30 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 30 milligramm

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets usp have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets usp have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown. the optimal duration of clopidogrel tablet usp therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets usp ha

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

dr.reddy's laboratories ltd. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder (mdd). efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. venlafaxine hydrochloride extended-release capsules are indicated for the treatment of generalized anxiety disorder (gad). efficacy was established in two 8-week and two 26-week placebo-controlled trials. venlafaxine hydrochloride extended-release capsules are indicated for the treatment of social anxiety disorder (sad), also known as social phobia. efficacy was established in four 12-week and one 26-week, placebo-controlled trials.   venlafaxine hydrochloride extended-release capsules are indicated for the treatment of panic disorder (pd), with or without agoraphobia. efficacy was established in two 12-week placebo-controlled trials. hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation the use of maois (intended to treat psychiat

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

dr. reddy's laboratories ltd - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 125 mg - divalproex sodium delayed-release capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. divalproex sodium delayed-release capsules are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures.  simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. because of the risk to the fetus of decreased iq, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women wit